University Of Heidelberg Medical Center

This phase 3 trial tests whether adding the drug isatuximab to standard treatment helps people with newly diagnosed multiple myeloma. About 662 participants will receive either standard therapy or standard therapy plus isatuximab. The goal is to see if the new combination leads t…